558
Participants
Start Date
January 31, 2006
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Lisinopril
Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
Telmisartan
Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Placebo
Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Standard Blood Pressure Control
Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Low Blood Pressure Control
Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Emory University School of Medicine, Atlanta
Cleveland Clinic Foundation, Cleveland
Mayo Clinic, Rochester
University of Kansas Medical Center, Kansas City
University of Colorado Health Sciences Center, Aurora
Tufts University-New England Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Polycystic Kidney Disease Foundation
OTHER
University of Pittsburgh
OTHER
Washington University School of Medicine
OTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH